These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 29377216)

  • 1. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
    Patten DK; Schultz BG; Berlau DJ
    Pharmacotherapy; 2018 Mar; 38(3):382-389. PubMed ID: 29377216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
    Trofimovitch D; Baumrucker SJ
    Am J Hosp Palliat Care; 2019 Oct; 36(10):907-912. PubMed ID: 30917675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low dose naltrexone for treatment of pain].
    Plesner KB; Vægter HB; Handberg G
    Ugeskr Laeger; 2015 Oct; 177(43):V03150248. PubMed ID: 26509454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
    Kim PS; Fishman MA
    Curr Pain Headache Rep; 2020 Aug; 24(10):64. PubMed ID: 32845365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
    Younger J; Mackey S
    Pain Med; 2009; 10(4):663-72. PubMed ID: 19453963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Dose Naltrexone in Dermatology.
    Jaros J; Lio P
    J Drugs Dermatol; 2019 Mar; 18(3):235-238. PubMed ID: 30909326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.
    Smith JP; Field D; Bingaman SI; Evans R; Mauger DT
    J Clin Gastroenterol; 2013 Apr; 47(4):339-45. PubMed ID: 23188075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Utilization of Low Dose Naltrexone for Chronic Pain.
    Poliwoda S; Noss B; Truong GTD; Creech ZA; Koushik SS; Urits I; Viswanath O
    CNS Drugs; 2023 Aug; 37(8):663-670. PubMed ID: 37505425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.
    Cote B; Ross B; Fortner J; Rao D
    Int J Pharm Compd; 2018; 22(3):252-256. PubMed ID: 29878893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
    Younger J; Parkitny L; McLain D
    Clin Rheumatol; 2014 Apr; 33(4):451-9. PubMed ID: 24526250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.
    Turel AP; Oh KH; Zagon IS; McLaughlin PJ
    J Clin Psychopharmacol; 2015 Oct; 35(5):609-11. PubMed ID: 26203498
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
    Smith JP; Bingaman SI; Ruggiero F; Mauger DT; Mukherjee A; McGovern CO; Zagon IS
    Dig Dis Sci; 2011 Jul; 56(7):2088-97. PubMed ID: 21380937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Naltrexone--high expectations to low dosages].
    Raknes G; Giverhaug T
    Tidsskr Nor Laegeforen; 2011 May; 131(8):844-6. PubMed ID: 21556092
    [No Abstract]   [Full Text] [Related]  

  • 17. Low Dose Naltrexone in the Treatment of Fibromyalgia.
    Metyas S; Chen CL; Yeter K; Solyman J; Arkfeld DG
    Curr Rheumatol Rev; 2018; 14(2):177-180. PubMed ID: 28325149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats.
    Tawfik DI; Osman AS; Tolba HM; Khattab A; Abdel-Salam LO; Kamel MM
    Neuropeptides; 2016 Oct; 59():39-45. PubMed ID: 27392602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of naltrexone in the treatment of chronic pain: a systematic review.
    Rassi-Mariani V; Barreto ESR; Antunes CR; Alencar VB; Falcão Lins-Kusterer LE; Azi LMTA; Kraychete DC
    Pain Manag; 2024; 14(8):453-463. PubMed ID: 39301937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells.
    Kučić N; Rački V; Šverko R; Vidović T; Grahovac I; Mršić-Pelčić J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.